Emma Walmsley, GlaxoSmithKline CEO (Mandel Ngan/AFP via Getty Images)
April 27, 2022 02:17 PM EDTUpdated April 29, 02:01 PM
Pharma

With a buy­out, planned spin­out and late-stage read­outs, GSK promis­es this will be a land­mark year

Paul Schloesser

Associate Editor

Amber Tong

Glax­o­SmithK­line CEO Em­ma Walm­s­ley has the Q1 sales num­bers to start off what she says will be a land­mark year. But de­liv­er­ing on the rest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times